Immutep Ltd ADR Total Liabilities
Immutep Ltd ADR total liabilities. Based on the latest financial reports, Immutep Ltd ADR (IMMP) has total liabilities worth $48.30 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Immutep Ltd ADR (IMMP) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Immutep Ltd ADR (2008–2025)
Total liabilities of Immutep Ltd ADR from 2008 to 2025. This chart illustrates how Immutep Ltd ADR's total liabilities have evolved over time, based on quarterly financial data.
Immutep Ltd ADR Competitors by Total Liabilities
The table below lists competitors of Immutep Ltd ADR ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Chuwa Wool Industry Co Taiwan Ltd
TW:1439
|
Taiwan | NT$2.55 Billion |
|
Kyungin Synthe
KO:012610
|
Korea | ₩290.57 Billion |
|
Yusin Holding Corp
TW:4557
|
Taiwan | NT$2.69 Billion |
|
Viet Nam Power Development JSC
VN:VPD
|
Vietnam | ₫361.15 Billion |
|
Phenixfin Corporation
NASDAQ:PFX
|
USA | $152.02 Billion |
|
LK CHEM
KQ:489500
|
Korea | ₩6.53 Billion |
|
Nova Minerals Limited
NYSE MKT:NVA
|
USA | $1.06 Billion |
Liability Composition Analysis (2008–2025)
This chart breaks down Immutep Ltd ADR's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Immutep Ltd ADR's balance sheet.
Liquidity & Leverage Metrics
Immutep Ltd ADR Total Liabilities Ratios Explained
Immutep Ltd ADR total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.97 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.49 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.33 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Immutep Ltd ADR's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Immutep Ltd ADR (2008–2025)
The table below shows the annual total liabilities of Immutep Ltd ADR from 2008 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $13.35 Million | +10.70% |
| 2024-06-30 | $12.06 Million | +9.82% |
| 2023-06-30 | $10.98 Million | +35.68% |
| 2022-06-30 | $8.09 Million | -7.61% |
| 2021-06-30 | $8.76 Million | -34.13% |
| 2020-06-30 | $13.30 Million | -17.68% |
| 2019-06-30 | $16.15 Million | +19.86% |
| 2018-06-30 | $13.48 Million | +59.84% |
| 2017-06-30 | $8.43 Million | +16.51% |
| 2016-06-30 | $7.24 Million | +14.98% |
| 2015-06-30 | $6.29 Million | +125.93% |
| 2014-06-30 | $2.79 Million | -21.88% |
| 2013-06-30 | $3.57 Million | -19.95% |
| 2012-06-30 | $4.45 Million | +75.28% |
| 2011-06-30 | $2.54 Million | +14.29% |
| 2010-06-30 | $2.22 Million | +228.41% |
| 2009-06-30 | $677.10K | +260.51% |
| 2008-06-30 | $187.82K | -- |
About Immutep Ltd ADR
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes… Read more